Drug Approval | April 17, 2026
Morepen Laboratories secures fourth consecutive USFDA ‘NIL 483’ inspection
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The inspection concluded with NIL observations
Sen spent a decade with Biocon and held various key roles,
The campaign seeks to raise awareness about hypertension while emphasising the significance of managing blood pressure for a healthier lifestyle
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
Themis will market this drug with the brand name REMITHEM.
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
Both products are broad-spectrum, foliar insecticides used across wide range of crops
Subscribe To Our Newsletter & Stay Updated
